COVID-19 - January 25, 2021
New data about AdaptVac’s cVLP based SARS-CoV-2 subunit vaccine
AdaptVac has announced the publication of strong virus neutralization animal proof-of-concept data for its capsid virus like particle (cVLP) based SARS-CoV-2 subunit vaccine in Nature Communications. The vaccine elicited antibodies in mice which effectively prevented live SARS-CoV-2 virus from infecting and killing human cells in an in vitro assay. The project remains on track for […]
Biotech Business - October 24, 2017
AdaptVac reaches proof of concept
ExpreS2ion’s new joint venture, AdaptVac, reaches proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. The scientific results that form the basis of the proof of concept in animal models show a strong therapeutic effect on par with leading treatments on the market. The data will […]